Biogen Inc. $BIIB Shares Sold by Profund Advisors LLC

Profund Advisors LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB) by 11.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,131 shares of the biotechnology company’s stock after selling 3,043 shares during the period. Profund Advisors LLC’s holdings in Biogen were worth $3,380,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BIIB. Oppenheimer & Co. Inc. grew its position in Biogen by 501.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 13,610 shares of the biotechnology company’s stock valued at $1,906,000 after buying an additional 11,346 shares during the last quarter. Waterfront Wealth Inc. acquired a new stake in shares of Biogen in the 3rd quarter worth $402,000. Smartleaf Asset Management LLC boosted its holdings in shares of Biogen by 210.9% in the third quarter. Smartleaf Asset Management LLC now owns 628 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 426 shares in the last quarter. Alps Advisors Inc. increased its stake in shares of Biogen by 24.2% during the third quarter. Alps Advisors Inc. now owns 3,143 shares of the biotechnology company’s stock worth $440,000 after acquiring an additional 612 shares during the period. Finally, MMA Asset Management LLC acquired a new position in shares of Biogen during the third quarter worth about $84,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wolfe Research set a $231.00 price objective on shares of Biogen in a research report on Monday. Oppenheimer increased their target price on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Stifel Nicolaus lifted their price target on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen increased their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday. Finally, UBS Group assumed coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price for the company. Thirteen research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $206.21.

Insider Buying and Selling

In related news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the transaction, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $193.81 on Tuesday. The stock has a market cap of $28.43 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.70 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The business has a fifty day moving average of $177.26 and a 200-day moving average of $157.48. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.